Your browser is no longer supported. Please, upgrade your browser.
IMRN Immuron Limited daily Stock Chart
Immuron Limited
Index- P/E- EPS (ttm)-0.68 Insider Own- Shs Outstand4.42M Perf Week-4.50%
Market Cap12.20M Forward P/E- EPS next Y- Insider Trans- Shs Float3.12M Perf Month7.81%
Income- PEG- EPS next Q- Inst Own3.06% Short Float0.12% Perf Quarter-10.97%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.02 Perf Half Y-59.37%
Book/sh1.76 P/B1.57 EPS next Y- ROA- Target Price- Perf Year-71.55%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.23 - 10.15 Perf YTD-52.41%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-72.81% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low23.71% ATR0.22
Employees- Current Ratio- Sales Q/Q52.50% Oper. Margin- RSI (14)45.46 Volatility4.04% 8.25%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.02 Prev Close2.75
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume202.92K Price2.76
Recom- SMA20-0.88% SMA50-9.18% SMA200-47.19% Volume4,545 Change0.36%
Sep-04-19 06:00AM  U.S. Defense Reports Immurons Travelan® demonstrates broad reactivity to Vibrio cholera strains from Southeast Asia indicating broad potential for prevention of travelers diarrhea GlobeNewswire +9.63%
Aug-16-19 06:00AM  Immuron to Commence Non-Deal Investor Roadshow GlobeNewswire
Aug-12-19 06:30AM  BriaCell Appoints Richard J. Berman to Board of Directors GlobeNewswire -8.31%
Aug-08-19 11:04PM  Some Immuron (ASX:IMC) Shareholders Have Copped A Big 67% Share Price Drop Simply Wall St. -6.50%
12:00PM  Immuron Reports Results in Severe Alcoholic Hepatitis Clinical Trial GlobeNewswire
Jul-17-19 11:39AM  A Look At Benzinga Pro's Most-Searched Tickers For July 17, 2019 Benzinga -12.79%
06:00AM  Immuron to Host Investor Webinar on July 18 to Provide Update on Recent Developments GlobeNewswire
06:00AM  Immuron Prices Underwritten Public Offering of ADSs GlobeNewswire
Jul-16-19 04:31PM  Immuron Announces Proposed Public Offering of ADSs GlobeNewswire +46.76%
12:44PM  A Look At Benzinga Pro's Most-Searched Tickers For July 16, 2019 Benzinga
06:00AM  Immuron North American revenue surges by 52% in FY19 GlobeNewswire
Jun-25-19 06:00AM  Immuron Directors Increase Shareholdings in the Company GlobeNewswire
Jun-19-19 08:00AM  Immuron to Commence US Non-Deal Institutional Investor Roadshow GlobeNewswire
Jun-12-19 02:30PM  Immuron Rips Higher On Positive Preclinical Results For Travelan Benzinga +14.52%
07:00AM  US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study GlobeNewswire
Jun-07-19 12:48AM  How Much Are Immuron Limited (ASX:IMC) Insiders Spending On Buying Shares? Simply Wall St. +5.08%
May-30-19 08:00AM  Immuron Announces the Closing of Public Offering of ADSs GlobeNewswire
May-23-19 09:10PM  Immuron Prices Underwritten Public Offering of ADSs GlobeNewswire
04:45PM  Immuron Announces Proposed Public Offering of ADSs GlobeNewswire
Apr-30-19 02:36PM  Immuron CEO Dr. Gary S. Jacob to Present at the ThinkEquity Conference on May 2, 2019 GlobeNewswire -5.26%
Apr-17-19 09:00AM  Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors GlobeNewswire
Apr-15-19 07:00PM  Do Institutions Own Immuron Limited (ASX:IMC) Shares? Simply Wall St. -9.71%
09:00AM  Immuron sales surge by 66% in the Third Quarter of FY19 GlobeNewswire
Apr-11-19 10:00AM  Immuron Receives U.S. Patent on Drug Composition to Treat Clostridium difficile GlobeNewswire +23.71%
09:00AM  Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers Diarrhea GlobeNewswire
Feb-11-19 07:14PM  What You Must Know About Immuron Limiteds (ASX:IMC) Financial Strength Simply Wall St.
Jan-29-19 09:30AM  Travelan® FY19 1st Half Update and Geographic Expansion into North America GlobeNewswire
Jan-08-19 02:32AM  Immuron Receives $1.19M R&D Tax Concession Refund GlobeNewswire
Nov-26-18 07:09PM  One Thing To Remember About The Immuron Limited (ASX:IMC) Share Price Simply Wall St.
Nov-19-18 09:00AM  Immuron Appoints Gary S. Jacob, Ph.D., Experienced US Based Biotechnology Executive, as CEO GlobeNewswire
Nov-09-18 06:00AM  NASH clinical trial presentation and continued revenue growth GlobeNewswire +16.79%
Sep-24-18 10:12PM  Could Immuron Limiteds (ASX:IMC) Investor Composition Impacts Your Returns? Simply Wall St.
Sep-05-18 10:00AM  US Department of Defense Reports Travelan Protects Against Shigella in Primates GlobeNewswire
Jul-25-18 10:00AM  Immuron Reports Record Revenue Exceeding AU$2 million for the FY18 year GlobeNewswire
Jul-24-18 06:30AM  Immuron Announces it has Received a European Patent Grant for NASH treatment GlobeNewswire
06:28AM  US Department of Defense Research Collaboration Moves Forward GlobeNewswire
Jun-25-18 08:36PM  Immuron Announces Board Appointment GlobeNewswire
May-07-18 09:43PM  Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program GlobeNewswire
Apr-23-18 06:57PM  Immuron CEO to Present at RedChip Global Online Growth Conference GlobeNewswire
09:30AM  Immurons Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets GlobeNewswire
Mar-13-18 06:20PM  Immuron Announces A$5.1M Private Placement to U.S. Fund GlobeNewswire +23.35%
09:30AM  Immuron Progresses Discussions with Institutional Funds GlobeNewswire
02:15AM  UPDATE -- Immuron Commences US Non-Deal Institutional Investor Roadshow GlobeNewswire
Mar-12-18 08:17AM  Immuron Commences US Non-Deal Institutional Investor Roadshow GlobeNewswire
Mar-07-18 06:30PM  Immuron Reports Positive Results in NASH Clinical Trial GlobeNewswire
05:06PM  Immuron Limited Issues Correction to Misleading Halt Announcement Headline GlobeNewswire
Feb-16-18 09:30AM  Travelan® Revenue Grows Significantly in US and Australia GlobeNewswire
Jan-31-18 09:30AM  Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI) GlobeNewswire +11.22%
Jan-29-18 09:20AM  US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella GlobeNewswire
Jan-24-18 09:30AM  Immuron to Receive $2.16M R&D Tax Concession Refund GlobeNewswire
Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company markets Travelan for the prevention of travelers' diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease. The company is also developing IMM-529, a clinical stage product for clostridium difficile infections. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research to develop a vaccine for a form of dysentery; and US Naval Medical Research Center to test the reactivity and therapeutic effectiveness of Travelan against Campylobacter and enterotoxigenic escherichia coli. Immuron Limited was founded in 1994 and is headquartered in Carlton, Australia.